Home » Stocks » MRTX

Mirati Therapeutics, Inc. (MRTX)

Stock Price: $195.47 USD -7.43 (-3.66%)
Updated Feb 25, 2021 3:59 PM EST - Market closed
Market Cap 10.29B
Revenue (ttm) 12.22M
Net Income (ttm) -329.23M
Shares Out 44.61M
EPS (ttm) -7.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $195.47
Previous Close $202.90
Change ($) -7.43
Change (%) -3.66%
Day's Open 199.69
Day's Range 194.05 - 204.97
Day's Volume 328,375
52-Week Range 66.01 - 249.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference ...

Seeking Alpha - 1 month ago

Leveraging sound science and prudent cancer treatment, Mirati is growing robustly. The two lead drugs (sitravatinib and Adagrasib) are rapidly advancing for different cancer indications.

InvestorPlace - 2 months ago

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, DNLI, NVAX, SGEN, ZLAB
Zacks Investment Research - 2 months ago

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29...

PRNewsWire - 3 months ago

SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended Septe...

Insider Monkey - 3 months ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

PRNewsWire - 3 months ago

SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of it...

Zacks Investment Research - 3 months ago

Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 3 months ago

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a pr...

GuruFocus - 3 months ago

Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (NASDAQ:MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at ...

The Motley Fool - 3 months ago

Which one of these biotech stocks has a better chance to provide market-beating gains?

Other stocks mentioned: AMGN
PRNewsWire - 3 months ago

SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares ...

Zacks Investment Research - 3 months ago

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 3 months ago

The biotech's positive clinical results announced on Sunday prompted analysts to boost their price targets on the stock.

Investors Business Daily - 3 months ago

Tiny Mirati Therapeutics posted positive preliminary data on a colorectal and lung cancer drug therapy in competition with drug giant Amgen, sending MRTX stock soaring to an all-time high. The...

PRNewsWire - 4 months ago

SAN DIEGO, Oct. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRA...

Newsfile Corp - 4 months ago

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of invest...

PRNewsWire - 4 months ago

SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), t...

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.

Seeking Alpha - 4 months ago

Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation.

Business Wire - 4 months ago

LOS ANGELES--(BUSINESS WIRE)---- $MRTX #MRTX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study ...

Business Wire - 5 months ago

INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 17...

Zacks Investment Research - 5 months ago

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 5 months ago

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.

PRNewsWire - 6 months ago

ANN ARBOR, Mich., Aug. 13, 2020 /PRNewswire/ -- Strata Oncology, Inc.

PRNewsWire - 6 months ago

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc.

GlobeNewsWire - 6 months ago

ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor

Zacks Investment Research - 6 months ago

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

NEW YORK, July 6, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" ...

Zacks Investment Research - 8 months ago

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 8 months ago

SAN DIEGO, June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41st Annual Goldman Sachs Global ...

PRNewsWire - 9 months ago

SAN DIEGO, May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Med...

PRNewsWire - 9 months ago

SAN DIEGO, May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's ...

Zacks Investment Research - 9 months ago

Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 10 months ago

Mirati Therapeutics, Inc.: Cracking KRAS Is Harder Than It Looks

Benzinga - 10 months ago

Mirati Therapeutics Inc (NASDAQ: MRTX) shares were seeing weakness Tuesday after short seller Kerrisdale Capital released a bleak report concerning its two investigational assets.

The Motley Fool - 10 months ago

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, AMRX, VKTX, VSTM
Zacks Investment Research - 1 year ago

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 1 year ago

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Other stocks mentioned: AMGN, RVMD
The Motley Fool - 1 year ago

Results from a combination study breathed life into the company's sitravatinib program.

Zacks Investment Research - 1 year ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: ANIP, IMMU, PTCT
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Mirati (MRTX) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Mirati Therapeutics: A Classic Philip Fisher Growth Stock

The Motley Fool - 1 year ago

MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.

Other stocks mentioned: IOVA, PSNL
The Motley Fool - 1 year ago

Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?

Other stocks mentioned: AMGN
The Motley Fool - 1 year ago

It’s looking competitive in one cancer drug class.

The Motley Fool - 1 year ago

This time, its own clinical trial is pushing the biotech higher.

About MRTX

Mirati Therapeutics, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It h... [Read more...]

Industry
Biotechnology
IPO Date
Jun 29, 2004
CEO
Charles Baum
Employees
111
Stock Exchange
NASDAQ
Ticker Symbol
MRTX
Full Company Profile

Financial Performance

In 2019, MRTX's revenue was $3.34 million, a decrease of -74.20% compared to the previous year's $12.93 million. Losses were -$213.26 million, 116.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 245.92, which is an increase of 25.81% from the latest price.

Price Target
$245.92
(25.81% upside)
Analyst Consensus: Buy